about
Control of bone mass and remodeling by PTH receptor signaling in osteocytesThe pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data.Increased nitric oxide-mediated vasodilation of bone resistance arteries is associated with increased trabecular bone volume after endurance training in rats.Bisphosphonate treatment modifies canine bone mineral and matrix properties and their heterogeneity.Bisphosphonates and osteonecrosis of the jaw: moving from the bedside to the bench.Skeletal effects of zoledronic acid in an animal model of chronic kidney diseaseCan deterministic mechanical size effects contribute to fracture and microdamage accumulation in trabecular bone?Effects of suppression of bone turnover on cortical and trabecular load sharing in the canine vertebral body.One year of alendronate treatment lowers microstructural stresses associated with trabecular microdamage initiation.Compromised osseous healing of dental extraction sites in zoledronic acid-treated dogs.Heritability of lumbar trabecular bone mechanical properties in baboons.In vivo effects of zoledronic acid on oral mucosal epithelial cellsAging and estrogen status: a possible endothelium-dependent vascular coupling mechanism in bone remodeling.Ovariectomy stimulates and bisphosphonates inhibit intracortical remodeling in the mouse mandible.Higher bone matrix density exists in only a subset of patients with bisphosphonate-related osteonecrosis of the jaw.Cancer treatment dosing regimens of zoledronic acid result in near-complete suppression of mandible intracortical bone remodeling in beagle dogsPTH receptor signaling in osteocytes governs periosteal bone formation and intracortical remodeling.Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice.Dietary phosphate restriction normalizes biochemical and skeletal abnormalities in a murine model of tumoral calcinosisSost downregulation and local Wnt signaling are required for the osteogenic response to mechanical loading.Cell autonomous requirement of connexin 43 for osteocyte survival: consequences for endocortical resorption and periosteal bone formation.Periosteum: biology, regulation, and response to osteoporosis therapies.Mandible matrix necrosis in beagle dogs after 3 years of daily oral bisphosphonate treatment.Absence of exposed bone following dental extraction in beagle dogs treated with 9 months of high-dose zoledronic acid combined with dexamethasoneReference point indentation is insufficient for detecting alterations in traditional mechanical properties of bone under common experimental conditions.Assessing the inter- and intra-animal variability of in vivo OsteoProbe skeletal measures in untreated dogs.Alendronate reduces bone toughness of ribs without significantly increasing microdamage accumulation in dogs following 3 years of daily treatment.Alendronate treatment results in similar levels of trabecular bone remodeling in the femoral neck and vertebra.Exercise-induced changes in the cortical bone of growing mice are bone- and gender-specificChanges in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate.Mandibular necrosis in beagle dogs treated with bisphosphonates.Bisphosphonate effects on bone turnover, microdamage, and mechanical properties: what we think we know and what we know that we don't know.The effects of bisphosphonates on jaw bone remodeling, tissue properties, and extraction healing.Effects of combination treatment with alendronate and raloxifene on skeletal properties in a beagle dog model.Greater magnitude of turnover suppression occurs earlier after treatment initiation with risedronate than alendronate.Differential skeletal responses of hindlimb unloaded rats on a vitamin D-deficient diet to 1,25-dihydroxyvitamin D3 and its analog, seocalcitol (EB1089).Bisphosphonate binding affinity affects drug distribution in both intracortical and trabecular bone of rabbits.Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate.Bisphosphonates do not alter the rate of secondary mineralization.Strontium ranelate does not stimulate bone formation in ovariectomized rats.
P50
Q27300741-166156AC-A5E6-42BB-A2C1-A72723355F4CQ33431056-302D1CE8-0B54-4850-8463-EBA59A496DC6Q33664728-FA9557CD-740E-4522-ADEB-7BF3E4F8F2A2Q33665130-420BDF87-6BB3-4542-9C39-7A247180E5C4Q33666457-9F230B16-1220-4E52-9428-135A266C2923Q33779709-E3C3E9B2-4643-4FF0-BAAB-1ECA157B9CFBQ33912859-8DBCCD14-F71D-4E2A-96A7-78E6CC37C0CFQ33923777-2755AB7C-EC3F-43D7-8A93-075CD864C129Q34053936-393D8C28-E6D5-4E2A-AE41-056BE1CEE992Q34393622-87521892-DD99-465A-91AF-B839174A2C4CQ34423326-FBB7A6D7-11A7-411D-8125-2D769830F618Q34441640-2BB4DF63-040A-48CB-8A6A-079FDDCA3596Q34489715-3039E466-86F2-4360-B28C-4017DB608A7BQ34635733-DBD4C42A-0223-4721-AEB3-CA737CC37148Q34987217-C11E43F7-9102-413C-88D0-500737EAE870Q35156035-23E1AC82-D279-4B71-B58A-726052EAD4BCQ35229920-D8A87A70-3397-4DBC-8DAC-51ACB3C4F506Q35558693-38D3617A-6A2A-4ACA-8E0B-240788401C27Q35590824-E773663A-00EB-48B0-BFEA-3D4286D3209CQ35635751-E5033588-57E3-4FE3-8792-02070DD15306Q35729489-0173859A-786A-4EB5-9E67-54E241FB6F39Q35948130-C9C3A496-97CF-4FBA-A36C-FF840B1F7128Q36766058-657CEDB3-F98D-4366-8069-94484AD61927Q36817027-CF1E5A29-53BC-48FD-BC36-A9ADD192F752Q36889120-5A37430B-9939-4B47-8E29-031AA448CE01Q37214385-9E9A117F-812E-47A0-A1ED-05E3869487F2Q37233303-5B4F456B-56C0-4561-8DD7-BB90B1CCE31BQ37233308-1D91328A-21FA-44EC-8BAB-92605D65FCE8Q37312455-091C6070-DFE0-493A-8471-B2A3A7A51D47Q37323596-B2938A28-956E-4908-B855-BB1BCE305027Q37396476-7261EFFE-49C5-46D7-94EE-13D71F73C033Q37801036-E5724D23-97C9-4A89-9B4F-176D8B2EFA86Q37832692-A8DEA1BD-93A9-4E02-B111-99F3082BA2F4Q38632055-ADF3AF7E-FA32-481D-8499-47D0D8297557Q43415166-1FBEB52D-9F17-4C11-A9B1-4EDCBDAB1929Q44944999-40919398-0306-4C88-83F2-7E1D98C0D02EQ45997666-50C002D7-5AF6-453D-AB9A-8FA9022354CBQ46281657-5F96E2D4-952A-4639-9220-7FA6909AE18DQ46293739-E90C9F23-9EC0-4B31-8D96-83019E3CDBE1Q46666653-8446D538-1128-48F5-8FAE-B3D224DE3FEE
P50
description
Amerikaans bioloog
@nl
bone biologist
@en
name
Matthew R. Allen
@ast
Matthew R. Allen
@ca
Matthew R. Allen
@en
Matthew R. Allen
@es
Matthew R. Allen
@fr
Matthew R. Allen
@nl
Matthew R. Allen
@sl
type
label
Matthew R. Allen
@ast
Matthew R. Allen
@ca
Matthew R. Allen
@en
Matthew R. Allen
@es
Matthew R. Allen
@fr
Matthew R. Allen
@nl
Matthew R. Allen
@sl
altLabel
Matt Allen
@en
prefLabel
Matthew R. Allen
@ast
Matthew R. Allen
@ca
Matthew R. Allen
@en
Matthew R. Allen
@es
Matthew R. Allen
@fr
Matthew R. Allen
@nl
Matthew R. Allen
@sl
P214
P244
P1053
A-8799-2015
P1153
7404104714
P21
P214
P244
no2006079629
P31
P3829
P496
0000-0002-1174-9004
P734
P735
P7859
lccn-no2006079629